Clinical Trial Update: Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery [Phase 1, Phase 2]

View source ↗

Summary

This document reports on a completed Phase 1/2 trial evaluating neoadjuvant cetuximab followed by curative surgery in head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED